Literature DB >> 10867206

Are cerebrovascular factors involved in Alzheimer's disease?

T Kudo1, K Imaizumi, H Tanimukai, T Katayama, N Sato, Y Nakamura, T Tanaka, Y Kashiwagi, Y Jinno, M Tohyama, M Takeda.   

Abstract

Recent epidemiological studies have shown that vascular risk factors may be involved in Alzheimer's disease (AD) as well as dementia in general. To investigate the relation between a vascular disorder and AD pathology, current criteria are defective because most depend on exclusion of a cerebrovascular disorder. Epidemiological studies have indicated the possibilities that arteriosclerosis, abnormal blood pressure, diabetes mellitus and smoking may be related to the pathogenesis of AD. As for the mechanism that vascular disorders influence AD, it is presumed that amyloid deposition may be caused by a vascular disorder. Alternatively, a vascular event may cause progression of subclinical AD to a clinical stage. Insulin resistance and apolipoprotein E may also be involved in these mechanisms. Our studies show that ischemia-induced the Alzheimer-associated gene presenilin 1 (PS1) and endoplasmic reticulum-stress, generated from a vascular disorder, may unmask clinical AD symptoms caused by presenilin mutation, suggesting that a vascular factor might be involved in the onset of familial AD.

Entities:  

Mesh:

Year:  2000        PMID: 10867206     DOI: 10.1016/s0197-4580(00)00129-9

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  16 in total

1.  Autoregulation of cerebral blood flow to changes in arterial pressure in mild Alzheimer's disease.

Authors:  Allyson R Zazulia; Tom O Videen; John C Morris; William J Powers
Journal:  J Cereb Blood Flow Metab       Date:  2010-08-25       Impact factor: 6.200

2.  Assessment of cognitive status in the elderly using telephone interviews.

Authors:  D Debling; M Amelang; P Hasselbach; T Stürmer
Journal:  Z Gerontol Geriatr       Date:  2005-10       Impact factor: 1.281

3.  Cerebrovascular blood flow velocities in pseudoexfoliation.

Authors:  Nurşen Yüksel; Yonca Anik; Aysun Kiliç; Vlevent Karabaş; Ali Demirci; Yusuf Cağlar
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-08-13       Impact factor: 3.117

4.  Down-regulation of parkin protein in transient focal cerebral ischemia: A link between stroke and degenerative disease?

Authors:  Thorsten Mengesdorf; Poul H Jensen; Gunter Mies; Christoph Aufenberg; Wulf Paschen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-01       Impact factor: 11.205

5.  Enhanced amyloidogenic processing of amyloid precursor protein and cell death under prolonged endoplasmic reticulum stress in brain endothelial cells.

Authors:  Ana I Plácido; Catarina R Oliveira; Paula I Moreira; Cláudia Maria F Pereira
Journal:  Mol Neurobiol       Date:  2014-08-17       Impact factor: 5.590

6.  Early growth response 1 (Egr-1) regulates phosphorylation of microtubule-associated protein tau in mammalian brain.

Authors:  Yifan Lu; Tong Li; Hamid Y Qureshi; Dong Han; Hemant K Paudel
Journal:  J Biol Chem       Date:  2011-04-13       Impact factor: 5.157

7.  A pilot study evaluating the efficacy and safety of rivastigmine in patients with mixed dementia.

Authors:  Steven G Potkin; Gus Alva; Ibrahim Gunay; Barbara Koumaras; Michael Chen; Dario Mirski
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

8.  Tissue transglutaminase, protein cross-linking and Alzheimer's disease: review and views.

Authors:  Deng-Shun Wang; Dennis W Dickson; James S Malter
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 9.  The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications.

Authors:  Qingguang Jiang; Michael Heneka; Gary E Landreth
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: a pilot-study.

Authors:  Josef Marksteiner; Douglas Imarhiagbe; Michaela Defrancesco; Eberhard A Deisenhammer; Georg Kemmler; Christian Humpel
Journal:  Exp Gerontol       Date:  2013-12-10       Impact factor: 4.032

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.